Strong Q2 For Cipla Amid Waning Generic Nexium Impact
This article was originally published in PharmAsia News
Executive Summary
Cipla has reported robust growth in the second quarter, buoyed by one-off revenues from the US, but the Indian company sought to temper full-year top-line expectations in view of the strong first-half showing.